Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Kane Biotech Inc V.KNE

Alternate Symbol(s):  KNBIF

Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.


TSXV:KNE - Post by User

Bullboard Posts
Post by Widwillyon Feb 26, 2018 8:52pm
187 Views
Post# 27625193

Kane sues Nestle

Kane sues Nestle

Kane Biotech Sues Nestl

WINNIPEG, Manitoba – (GlobeNewswire – February 26, 2018) – Kane Biotech Inc. (TSX-V:KNE, OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”) today announced that it has filed a lawsuit against Nestec, Ltd., a/k/a Nestec, S.A. (“Nestec”), and Nestl Purina Petcare Global Resources, Inc.  (“Nestl Purina”), (collectively “Nestl”) for breach of agreements between the parties, and misappropriation of Kane Biotech’s trade secrets and intellectual property.   In the six-count complaint filed under seal in U.S. federal court in Missouri, Kane Biotech alleges, amongst other improper activities, that a Nestl patent application makes improper use of Kane Biotech’s patent rights for oral care, personal care and wound care antimicrobial and anti-biofilm technologies that the Corporation developed.

Mark Ahrens-Townsend, President & CEO of Kane Biotech, said, "Kane Biotech has invested significantly in its intellectual property and it will vigorously protect and defend its interests and the interests of its shareholders against anyone who seeks to profit from it without proper compensation to our Corporation.
Bullboard Posts